TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05474703

Intervention type: OTHER
Intervention: SF-36 Scores
Description: From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied.

Intervention type: OTHER
Intervention: SF-36 Scores
Description: From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied.
Study: NCT05611255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic Intermittent Catheterization
Description: A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Scan Guided Catheterization
Description: A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
Study: NCT04804696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg I.V. drip on days 1 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
Study: NCT05656222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA combination treatment
Description: a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
Study: NCT06275997

Intervention type: DEVICE
Group type: OTHER
Intervention: Integration of Artificial Intelligence (AI) assistance to screening gastroscopy
Description: Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integration of Artificial Intelligence (AI) assistance to screening gastroscopy
Description: Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integration of Artificial Intelligence (AI) assistance to screening gastroscopy
Description: Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems.
Study: NCT05834101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial Release
Description: Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic streching
Description: The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
Study: NCT05434104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal lactoferrin
Description: Lactoferrin vaginal pessaries to insert nightly for seven nights

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
Study: NCT04684576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permobil Explorer Mini
Description: The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permobil Explorer Mini
Description: The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Ride-On Car
Description: Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Ride-On Car
Description: Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
Study: NCT06290661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active electrostimulation
Description: Maintain the electrical stimulation state, and according to the patient's feeling to set the appropriate stimulation parameter range (pain relief and no obvious numbness and discomfort), the programme will be written into the patient's self-control remote control, by the patient according to their own pain situation for the independent control of the stimulation current.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo electrostimulation
Description: No actual electrostimulation
Study: NCT05970185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
Study: NCT05205616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonopet ultrasonic saw
Description: Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reciprocating saw
Description: See above description
Study: NCT06095947

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Description: A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Description: A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
Study: NCT05119517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative medicine pedal pump
Description: In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
Study: NCT06262880

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant derived phenolics
Description: Dietary supplement containing plant derived phenolics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant derived phenolics
Description: Dietary supplement containing plant derived phenolics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystaline cellulose (MCC)
Description: Placebo treatment: Microcrystaline cellulose
Study: NCT06022744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX109
Description: LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
Study: NCT06145802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT316
Description: Autologous Tumor Infiltrating Lymphocyte Injection
Study: NCT04907513

Intervention type: OTHER
Intervention: Assessment of the Motivational State
Description: A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
Study: NCT05205798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food consumption using plates with a diameter of 23 cm.
Description: In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Washout period
Description: No interventional food consumption for 1 week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food consumption using plates with a diameter of 31 cm.
Description: In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
Study: NCT05663346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabis & Cancer digital educational intervention
Description: The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard information regarding cannabis use in oncology
Description: Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
Study: NCT06507605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
Study: NCT06182098

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1/2 maintenance fluids
Description: Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 0.5mg/kg, with a maximum of 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: 0.5mg/kg, with a maximum of 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 0.5mg/kg, with a maximum of 25mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: 0.5mg/kg, with a maximum of 25mg
Study: NCT06507605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21
Description: R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
Study: NCT04802382

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: patients will receive the placebo treatment in addition to Standard of Care
Study: NCT06182098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: 0.15mg/kg, with a maximum of 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prochlorperazine
Description: 0.15mg/kg, with a maximum of 10mg
Study: NCT04802382

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Confirm SARS-CoV-2 infection
Description: patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Study: NCT06182098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bolus
Description: 20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
Study: NCT04802382

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Confirm SARS-CoV-2 infection
Description: patients will be tested for SARS-CoV-2 on days 1, 14 and 28

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Confirm SARS-CoV-2 infection
Description: patients will be tested for SARS-CoV-2 on days 1, 14 and 28
Study: NCT05454462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP Application KM-001
Description: KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP Application KM-001
Description: KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
Study: NCT04802382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: patients will undergo a physical examination on days 1-14 and day 28

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: patients will undergo a physical examination on days 1-14 and day 28

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Examination
Description: patients will undergo a physical examination on days 1-14 and day 28

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: patient's vital signs will be measured on days 1-14 and day 28